Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2021-02-02 Regulatory Filings
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
Marketing materials - French.pdf
Regulatory Filings
2021-02-02 English
News release - English.pdf
Regulatory Filings
2021-02-02 English
News release - English.pdf
Regulatory Filings
2021-02-02 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the renewal and expansion of a distribution agreement for a pharmaceutical product (NYDA®) in Canada. It contains no financial statements, no regulatory form references, no voting results, no management or board changes, no earnings data, and no detailed financial or strategic presentation. It is a corporate announcement about a commercial agreement renewal and expansion. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to business agreements impacting the company's commercial operations and potentially its capital structure or revenue streams. The document length is short (2807 characters), and it is not an announcement of a report publication or a certification. Therefore, the most appropriate classification is CAP with high confidence.
2021-01-25 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Medexus Pharmaceuticals Inc. has submitted an application to list its shares on the Nasdaq Capital Market. It includes statements from the CEO about the significance of this milestone, details about the company's growth, and plans to maintain current listings on other exchanges. Additionally, it announces an upcoming investor update webinar. The content focuses on a capital market listing application and investor communication rather than financial results, management changes, or regulatory filings. There are no financial statements or detailed financial data presented, nor is this a report or transcript. The document is an update on financing/capital structure activity (application to list on Nasdaq) and an investor event announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-01-21 English
Notice of the meeting and record date - French.pdf
Regulatory Filings Classification · 95% confidence The document is a notification regarding the upcoming extraordinary meeting of shareholders for Medexus Pharmaceuticals Inc. It provides details such as the meeting type, dates for registration and voting, and logistical information about the meeting. The document does not contain any financial data, management discussion, or detailed report content. It is essentially an announcement about the meeting and voting procedures, not the meeting materials or results themselves. Given the short length (1318 characters) and the nature of the content, this fits best as a Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly a Regulatory Filing (RNS). However, since it is about the meeting notice and voting rights, the closest specific category is DVA, which covers official results and voting rights announcements. But since this is a notice of the meeting and voting rights, not the results, it is more appropriate to classify it as Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements including meeting notices and voting rights information that are not results or materials. Therefore, the best classification is Regulatory Filings (RNS).
2021-01-11 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.